102 related articles for article (PubMed ID: 24090479)
1. Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients.
Scartozzi M; Giampieri R; Loretelli C; Bittoni A; Mandolesi A; Faloppi L; Bianconi M; Del Prete M; Andrikou K; Bearzi I; Cascinu S
Pharmacogenomics; 2013 Dec; 14(16):1991-8. PubMed ID: 24090479
[TBL] [Abstract][Full Text] [Related]
2. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.
Scartozzi M; Faloppi L; Svegliati Baroni G; Loretelli C; Piscaglia F; Iavarone M; Toniutto P; Fava G; De Minicis S; Mandolesi A; Bianconi M; Giampieri R; Granito A; Facchetti F; Bitetto D; Marinelli S; Venerandi L; Vavassori S; Gemini S; D'Errico A; Colombo M; Bolondi L; Bearzi I; Benedetti A; Cascinu S
Int J Cancer; 2014 Sep; 135(5):1247-56. PubMed ID: 24510746
[TBL] [Abstract][Full Text] [Related]
3. Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.
Vahdat LT; Layman R; Yardley DA; Gradishar W; Salkeni MA; Joy AA; Garcia AA; Ward P; Khatcheressian J; Sparano J; Rodriguez G; Tang S; Gao L; Dalal RP; Kauh J; Miller K
Oncologist; 2017 Mar; 22(3):245-254. PubMed ID: 28220020
[TBL] [Abstract][Full Text] [Related]
4. Discovery and validation of vascular endothelial growth factor (VEGF) pathway polymorphisms in esophageal adenocarcinoma outcome.
Eng L; Azad AK; Qiu X; Kong QQ; Cheng D; Ying N; Tse A; Kuang Q; Dodbiba L; Renouf DJ; Marsh S; Savas S; Mackay HJ; Knox JJ; Darling GE; Wong RK; Xu W; Liu G; Faluyi OO
Carcinogenesis; 2015 Sep; 36(9):956-62. PubMed ID: 26014353
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.
Van Cutsem E; de Haas S; Kang YK; Ohtsu A; Tebbutt NC; Ming Xu J; Peng Yong W; Langer B; Delmar P; Scherer SJ; Shah MA
J Clin Oncol; 2012 Jun; 30(17):2119-27. PubMed ID: 22565005
[TBL] [Abstract][Full Text] [Related]
6. Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.
Gampenrieder SP; Hufnagl C; Brechelmacher S; Huemer F; Hackl H; Rinnerthaler G; Romeder F; Monzo Fuentes C; Morre P; Hauser-Kronberger C; Mlineritsch B; Greil R
Pharmacogenomics J; 2017 Jul; 17(4):344-350. PubMed ID: 27139155
[TBL] [Abstract][Full Text] [Related]
7. Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer.
Hirashima Y; Yamada Y; Matsubara J; Takahari D; Okita N; Takashima A; Kato K; Hamaguchi T; Shirao K; Shimada Y; Taniguchi H; Shimoda T
Cancer Sci; 2009 Feb; 100(2):310-5. PubMed ID: 19068081
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma.
Jüttner S; Wissmann C; Jöns T; Vieth M; Hertel J; Gretschel S; Schlag PM; Kemmner W; Höcker M
J Clin Oncol; 2006 Jan; 24(2):228-40. PubMed ID: 16344322
[TBL] [Abstract][Full Text] [Related]
9. Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer.
Pallaud C; Reck M; Juhasz E; Szima B; Yu CJ; Burdaeva O; Orlov S; Hilton M; Archer V; Mok T
Lung Cancer; 2014 Oct; 86(1):67-72. PubMed ID: 25154982
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival.
Tzanakis N; Gazouli M; Rallis G; Giannopoulos G; Papaconstantinou I; Theodoropoulos G; Pikoulis E; Tsigris C; Karakitsos P; Peros G; Nikiteas N
J Surg Oncol; 2006 Dec; 94(7):624-30. PubMed ID: 17111394
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma.
Kolev Y; Uetake H; Iida S; Ishikawa T; Kawano T; Sugihara K
Ann Surg Oncol; 2007 Oct; 14(10):2738-47. PubMed ID: 17687613
[TBL] [Abstract][Full Text] [Related]
12. Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival.
Paiva TF; de Jesus VH; Marques RA; da Costa AA; de Macedo MP; Peresi PM; Damascena A; Rossi BM; Begnami MD; de Lima VC
BMC Cancer; 2015 Sep; 15():643. PubMed ID: 26394830
[TBL] [Abstract][Full Text] [Related]
13. Gastric cancer risk predisposition and prognostic significance of vascular endothelial growth factor (VEGF) gene polymorphisms--a case-control study in an Omani population.
Al-Moundhri MS; Al-Nabhani M; Burney IA; Al-Farsi AA; Al-Bahrani B
Mol Carcinog; 2009 Dec; 48(12):1170-6. PubMed ID: 19676106
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib).
Wilson PM; Yang D; Azuma M; Shi MM; Danenberg KD; Lebwohl D; Sherrod A; Ladner RD; Zhang W; Danenberg PV; Trarbach T; Folprecht G; Meinhardt G; Lenz HJ
Pharmacogenomics J; 2013 Oct; 13(5):410-6. PubMed ID: 22664478
[TBL] [Abstract][Full Text] [Related]
15. VEGFA, FLT1, KDR and colorectal cancer: assessment of disease risk, tumor molecular phenotype, and survival.
Slattery ML; Lundgreen A; Wolff RK
Mol Carcinog; 2014 Feb; 53 Suppl 1():E140-50. PubMed ID: 23794399
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel.
Koutras AK; Kotoula V; Papadimitriou C; Dionysopoulos D; Zagouri F; Kalofonos HP; Kourea HP; Skarlos DV; Samantas E; Papadopoulou K; Kosmidis P; Pectasides D; Fountzilas G
Pharmacogenomics J; 2014 Jun; 14(3):248-55. PubMed ID: 24061601
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
Wong NS; Buckman RA; Clemons M; Verma S; Dent S; Trudeau ME; Roche K; Ebos J; Kerbel R; Deboer GE; Sutherland DJ; Emmenegger U; Slingerland J; Gardner S; Pritchard KI
J Clin Oncol; 2010 Feb; 28(5):723-30. PubMed ID: 20026801
[TBL] [Abstract][Full Text] [Related]
18. Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D.
Miyata Y; Kanda S; Ohba K; Nomata K; Hayashida Y; Eguchi J; Hayashi T; Kanetake H
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):800-6. PubMed ID: 16467091
[TBL] [Abstract][Full Text] [Related]
19. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer.
Takahashi Y; Cleary KR; Mai M; Kitadai Y; Bucana CD; Ellis LM
Clin Cancer Res; 1996 Oct; 2(10):1679-84. PubMed ID: 9816116
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial.
Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G
Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
